Skip to main content
ABEO
NASDAQ Life Sciences

Abeona Buys Phase 3 EoE Drug, Raises $30M at $3.75 a Share

Tom Rudovsky · Reported by Benzinga
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.615
Mkt Cap
$149.822M
52W Low
$2.3
52W High
$7.65
52W Position info
14% above low
Off High info
66% below high
Rel. Volume info
5.2× avg
Market data snapshot near publication time

ABEO is trading near its 52-week low of $2.3 (14% above the low) on elevated volume (5.2× avg).

Summary

Abeona is adding a second late-stage asset, acquiring APT-1011 (now ABO-801) from Ellodi Pharmaceuticals for $20 million in stock with no upfront cash, plus up to $30 million on regulatory approval, up to $30 million in sales milestones and tiered royalties. The once-daily oral tablet targets eosinophilic esophagitis, a condition affecting roughly 360,000 people in the U.S.; Abeona plans to start a Phase 3 trial in mid-2027 with topline data expected late 2028. To fund it, the company raised $30 million in a private placement at $3.75 a share — 6.4 million shares plus pre-funded warrants for about 1.6 million shares — with Nantahala, Marshall Wace and Perceptive participating. Q3 muddied the picture: revenue of $13.491 million missed the $16.484 million consensus even as the 8-cent loss beat the 15-cent estimate, and ZEVASKYN product revenue rose 18% sequentially to $13.5 million with 15 total patient treatments since launch. Cash stood at $134.9 million before the placement, and shares were down 11.51% at $3.69 premarket.

At the time of this announcement, ABEO was trading at $2.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.8M. The 52-week trading range was $2.30 to $7.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

ABEO - Latest Insights

ABEO
Nov 09, 2026, 6:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $2.61 info
Change: -$1.40 (-35%) info
Market Cap: $148.964M info
ABEO
Nov 09, 2026, 6:35 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $2.61 info
Change: -$1.40 (-35%) info
Market Cap: $148.964M info
ABEO
Nov 09, 2026, 6:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $2.61 info
Change: -$1.57 (-38%) info
Market Cap: $148.964M info
ABEO
Nov 09, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $2.61 info
Change: -$1.57 (-38%) info
Market Cap: $148.964M info
ABEO
Oct 23, 2026, 2:38 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $4.32
Real-time Price: $2.61 info
Change: -$1.72 (-40%) info
Market Cap: $148.964M info